Press Releases

9 Feb 2021

Updated 2 Nov 2021

Newly formed data science group created from XClinical, Carenity, and Fortress Medical, to rename as EvidentIQ Group, and brings two life science veterans onboard


Newly formed data science group created from XClinical, Carenity, and Fortress Medical, to rename as EvidentIQ Group, and brings two life science veterans onboard

MUNICH, Germany, Feb. 9th, 2021 – The newly formed life science group that resulted from the merger of clinical software vendors XClinical and Fortress Medical with social platform Carenity, announced to rename itself to EvidentIQ Group.

The EvidentIQ offering brings an innovative end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with its suite of applications, including EDC, coding, remote monitoring, Risk-based Monitoring, ePRO, eTMF, CTMS, RTMS, Payments, and eFeasibility within a single integrated cloud platform. By combining the platform with a broad data science service portfolio such as patient recruitment, patient engagement media, and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing, and reimbursement needs.

Andreas Weber appointed new CEO

Today it was announced that Andreas Weber has been appointed CEO of EvidentIQ, leading the group’s strategy and operations. Andreas brings in more than 20 years of industry experience and looks back on a career with top management positions at ERT, Bioclinica and Oracle Health Sciences.

In a statement to disclose the new name and future positioning of the group, Weber said:

“By evolving into a next generation technology amplified data science group, EvidentIQ is paving the way for a new standard in value creation and innovation driven relevance for its customers.”

“Our customers across XClinical, Carenity and Fortress Medical are at the heart of everything we do. As such, I wanted to assure our current loyal and valued customers, that not only will we continue the existing solutions and support offerings, we will in fact be expanding them technologically as well as increasing their interoperability.”

Lewis Baird to take over CCO role

Seconding Mr. Weber, Lewis Baird will take over the sales responsibility as Chief Commercial Officer with EvidentIQ. Before joining EvidentIQ, Lewis established and led the European commercial team at Medrio. Prior to Medrio, Lewis held commercial leadership roles at DataTrial, Biorasi and Quintiles.

Together with Manuel Neukum (Chief Operations Officer), Michael Chekroun (Chief Strategy and Transformation Officer) and Roland Hiltmann (Chief Financial Officer), Lewis is part of Andreas Weber’s Executive Management Team.

Today EvidentIQ already supports 7 of the top 10 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including the US, Germany, France, UK, Italy, Japan, and China.

Image Credit: iStock

Get a Demo

Let us show you how we can help you.

Get a Quote

Discover a solution tailored to your needs and budget.

Get a Meeting

Let’s start a new project together!

Let’s Start
a conversation

Ready to discover how our platform and its suite of applications can meet your needs?


    We use cookies to personalize content and ads, provide social media features, and analyze traffic to our website. Our partners may combine this information with other data they have provided to you or collected from your use of the services. Because we value your privacy, we hereby request your permission to use the following technologies. You may change / revoke your consent later at any time by clicking on the settings in the lower left corner of the page.

    Please note that according to a recent ruling by the European Court of Justice (ECJ), there is no adequate level of data protection in the USA and therefore a risk to the protection of your data. For example, under certain conditions, your data may be processed by US authorities for control and monitoring purposes. In addition, we currently refer to Art. 49 GDPR with regard to the legal basis for the transfer of data. After implementation of the new EU standard data protection clauses, these will constitute the legal basis for data transfer to third countries.